Therapeutic successes and a trend toward delaying childbearing now permit survivors of breast, ovarian, endometrial, and cervical cancers to consider future fertility. How should this affect the advice you offer your patients?
Tebipenem HBr cUTI trial ends early after meeting efficacy goals
May 28th 2025GSK and Spero Therapeutics announced that the phase 3 PIVOT-PO trial for tebipenem HBr, a potential first oral carbapenem for cUTIs in the United States, was stopped early because of positive efficacy results.
Read More